Last reviewed · How we verify
CoronoVAC
CoronoVAC is a COVID-19 vaccine candidate designed to elicit immune responses against SARS-CoV-2.
CoronoVAC is a COVID-19 vaccine candidate designed to elicit immune responses against SARS-CoV-2. Used for COVID-19 prevention.
At a glance
| Generic name | CoronoVAC |
|---|---|
| Sponsor | Asoc. Prof. Erdoğan Selçuk Şeber |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
CoronoVAC is an inactivated or protein-based vaccine in development to prevent COVID-19 infection by stimulating both humoral and cellular immune responses against SARS-CoV-2 antigens. The vaccine aims to generate neutralizing antibodies and T-cell responses to protect against infection and severe disease. As a Phase 2 candidate, it is being evaluated for safety, tolerability, and immunogenicity in human subjects.
Approved indications
- COVID-19 prevention
Common side effects
- Injection site pain or erythema
- Fever
- Fatigue
- Myalgia
Key clinical trials
- Investigation of the Effectiveness of CoronaVac Vaccine in Cancer Patients With Active Chemotherapy and Comparison With Healthy People.
- Oxidative Stress Parameters, Trace Element and Quality of Life in Women Before and After Covid-19 Vaccines (NA)
- Oxidative Stress Parameters, Trace Element and Quality of Life in Men Before and After Covid-19 Vaccines (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CoronoVAC CI brief — competitive landscape report
- CoronoVAC updates RSS · CI watch RSS
- Asoc. Prof. Erdoğan Selçuk Şeber portfolio CI